Alzheimer’s Drug Used Mainly by Relatively Affluent, Urban White Men

(MedPage Today) — Uptake of lecanemab (Leqembi), a monoclonal antibody approved to treat early Alzheimer’s disease, appeared to be marked by racial, ethnic, and socioeconomic disparities, an analysis of Medicare data suggested.
Of all Medicare…